Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use

Regorafenib for Gastrointestinal Malignancies

(2013) Giuseppe Aprile et al.   BIODRUGS

Rationale and clinical use of multitargeting anticancer agents

(2013) Davide Melisi et al.   CURRENT OPINION IN PHARMACOLOGY

The Neuropilin 1 Cytoplasmic Domain Is Required for VEGF-A-Dependent Arteriogenesis

(2013) Anthony Lanahan et al.   DEVELOPMENTAL CELL

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

(2013) Jeffrey Melson Clarke et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

(2013) Christian Rolfo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Ramucirumab: a novel antiangiogenic agent

(2013) Roopma Wadhwa et al.   Future Oncology

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

(2013) Robert J Motzer et al.   LANCET ONCOLOGY

Is There a Role for Bevacizumab in the Treatment of Glioblastoma?

(2013) A. S. Chi et al.   ONCOLOGIST

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)

(2012) Corey J. Langer et al.   CANCER TREATMENT REVIEWS

Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2012) R. S. Finn et al.   CLINICAL CANCER RESEARCH

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

(2012) Edward B. Garon et al.   Clinical Lung Cancer

Antibody Phage Display Libraries: Contributions to Oncology

(2012) Carmela Dantas-Barbosa et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

(2012) Jin Soo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

(2012) Paulo M. Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

(2012) Jung Hun Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

(2012) Hans-Joachim Schmoll et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications

(2012) Catherine Frenette   WORLD JOURNAL OF GASTROENTEROLOGY

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

(2011) Peter C. Thuss-Patience et al.   EUROPEAN JOURNAL OF CANCER

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Signaling Pathways in Hepatocellular Carcinoma

(2011) Daniela Sia et al.   ONCOLOGY

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies

(2011) Matthew C. Franklin et al.   STRUCTURE

A New BATTLE in the Evolving War on Cancer

(2011) Lecia V. Sequist et al.   Cancer Discovery

Structural determinants of vascular endothelial growth factor-D receptor binding and specificity

(2010) V.-M. Leppanen et al.   BLOOD

Angiogenesis Inhibitors: Current Strategies and Future Prospects

(2010) K. M. Cook et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ramucirumab (IMC-1121B): a novel attack on angiogenesis

(2010) Jennifer L Spratlin et al.   Future Oncology

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action

(2010) Napoleone Ferrara   MOLECULAR BIOLOGY OF THE CELL

TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer

(2009) John Mackey et al.   Clinical Breast Cancer

Current status and future prospects for anti-angiogenic therapies in cancer

(2009) Carolyn A Staton et al.   Expert Opinion on Drug Discovery

Sunitinib in solid tumors

(2009) Hui K Gan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE